EU/3/14/1342

About

On 15 October 2014, orphan designation (EU/3/14/1342) was granted by the European Commission to S-cubed Limited, United Kingdom, for glucagon for the treatment of congenital hyperinsulinism.

The sponsorship was transferred to S-cubed Pharmaceutical Services ApS, Denmark, in January 2019.

Key facts

Active substance
Glucagon
Disease / condition
Treatment of congenital hyperinsulinism
Date of first decision
08/10/2009
Outcome
Positive
EU designation number
EU/3/14/1342

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

S-cubed Pharmaceutical Services ApS
David Balfours Gade 4, St., Tv
Copenhagen K
Hovedstaden 1402
Denmark
Tel. +45 3145 2916
E-mail: info@s-cubed-global.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating